PhytoMedical Technologies, Inc.’s In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results

PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced the results of its anti-cancer compound in vivo toxicity and efficacy tests on HCT116 human colon cancer cells was successful. “I am encouraged by the results of our human colon cancer toxicity and efficacy tests which is allowing us to continue to climb our developmental ladder,” stated Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc. “We have made some significant progress this past year and look forward to moving to the next phase in our developmental pathway.”